RS51082B - Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol - Google Patents

Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol

Info

Publication number
RS51082B
RS51082B YUP-2005/0383A YUP20050383A RS51082B RS 51082 B RS51082 B RS 51082B YU P20050383 A YUP20050383 A YU P20050383A RS 51082 B RS51082 B RS 51082B
Authority
RS
Serbia
Prior art keywords
formoterol
roflumilast
administered
acceptable salt
pharmacologically acceptable
Prior art date
Application number
YUP-2005/0383A
Other languages
English (en)
Serbian (sr)
Inventor
Degenhard Dr. Marx
Christian Dr. Weimar
Daniela Dr. Bundschuh
Rolf Dr. Beume
Stefan-Lutz dr. WOLLIN
Original Assignee
Nycomed Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh. filed Critical Nycomed Gmbh.
Publication of RS20050383A publication Critical patent/RS20050383A/sr
Publication of RS51082B publication Critical patent/RS51082B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YUP-2005/0383A 2002-11-27 2003-11-26 Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol RS51082B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026504 2002-11-27
PCT/EP2003/013266 WO2004047828A1 (en) 2002-11-27 2003-11-26 Synergistic combination compresing roflumilas and (r.r) -formoterol

Publications (2)

Publication Number Publication Date
RS20050383A RS20050383A (sr) 2007-08-03
RS51082B true RS51082B (sr) 2010-10-31

Family

ID=32338001

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0383A RS51082B (sr) 2002-11-27 2003-11-26 Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol

Country Status (31)

Country Link
US (1) US20060199865A1 (enExample)
EP (1) EP1567140B1 (enExample)
JP (1) JP2006508993A (enExample)
KR (1) KR20050094810A (enExample)
CN (1) CN1713902A (enExample)
AT (1) ATE399544T1 (enExample)
AU (1) AU2003288169B8 (enExample)
BR (1) BR0316475A (enExample)
CA (1) CA2506956C (enExample)
CO (1) CO5690571A2 (enExample)
CY (1) CY1110368T1 (enExample)
DE (1) DE60321954D1 (enExample)
DK (1) DK1567140T3 (enExample)
EA (1) EA009990B1 (enExample)
ES (1) ES2309374T3 (enExample)
HR (1) HRP20050580B1 (enExample)
IL (1) IL168307A (enExample)
IS (1) IS2576B (enExample)
MA (1) MA27538A1 (enExample)
ME (1) ME00488B (enExample)
MX (1) MXPA05005438A (enExample)
NO (1) NO334148B1 (enExample)
NZ (1) NZ540658A (enExample)
PL (1) PL214869B1 (enExample)
PT (1) PT1567140E (enExample)
RS (1) RS51082B (enExample)
SI (1) SI1567140T1 (enExample)
TN (1) TNSN05130A1 (enExample)
UA (1) UA83017C2 (enExample)
WO (1) WO2004047828A1 (enExample)
ZA (1) ZA200503307B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
EP2258350B1 (en) 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
CN103784443A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含沙美特罗和罗氟司特的药物组合产品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
EP0938467B1 (en) * 1996-11-11 2002-06-12 Sepracor, Inc. Process for the preparation of optically pure isomers of formoterol
TR199901772T2 (enExample) * 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
JP2001513097A (ja) * 1997-02-28 2001-08-28 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Pde−抑制物質とアデニル酸シクラーゼ・アゴニストもしくはグアニル酸シクラーゼ・アゴニストとからなる相乗的組み合わせ組成物
KR20010072931A (ko) * 1998-08-26 2001-07-31 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 폐 질환 치료 요법
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
CZ302882B6 (cs) * 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7045658B2 (en) * 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
CA2445839A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha

Also Published As

Publication number Publication date
CN1713902A (zh) 2005-12-28
IS7899A (is) 2005-06-20
EA200500865A1 (ru) 2005-12-29
DK1567140T3 (da) 2008-11-03
ZA200503307B (en) 2006-11-29
RS20050383A (sr) 2007-08-03
EP1567140A1 (en) 2005-08-31
IS2576B (is) 2010-02-15
IL168307A (en) 2010-12-30
KR20050094810A (ko) 2005-09-28
AU2003288169B2 (en) 2010-01-07
MA27538A1 (fr) 2005-09-01
AU2003288169A1 (en) 2004-06-18
TNSN05130A1 (en) 2007-05-14
PL375632A1 (en) 2005-12-12
HK1081862A1 (en) 2006-05-26
CY1110368T1 (el) 2015-04-29
CA2506956A1 (en) 2004-06-10
PT1567140E (pt) 2008-09-24
EP1567140B1 (en) 2008-07-02
HRP20050580A2 (en) 2006-08-31
ATE399544T1 (de) 2008-07-15
UA83017C2 (uk) 2008-06-10
NO334148B1 (no) 2013-12-16
AU2003288169B8 (en) 2010-08-26
ME00488B (me) 2011-10-10
MXPA05005438A (es) 2005-08-03
US20060199865A1 (en) 2006-09-07
NO20053023L (no) 2005-06-20
CA2506956C (en) 2012-10-02
HRP20050580B1 (hr) 2014-04-11
ES2309374T3 (es) 2008-12-16
EA009990B1 (ru) 2008-04-28
NZ540658A (en) 2007-03-30
JP2006508993A (ja) 2006-03-16
BR0316475A (pt) 2005-10-11
WO2004047828A1 (en) 2004-06-10
PL214869B1 (pl) 2013-09-30
CO5690571A2 (es) 2006-10-31
DE60321954D1 (de) 2008-08-14
SI1567140T1 (sl) 2008-12-31

Similar Documents

Publication Publication Date Title
PL200923B1 (pl) Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
SK285884B6 (sk) Kombinovaný prípravok formoterolu a tiotrópiovej soli, jeho použitie a farmaceutická súprava, ktoráho obsahuje
KR20050104367A (ko) 타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물
KR20070042917A (ko) 소아 천식의 치료
AU2003292120B2 (en) New synergistic combination comprising roflumilast and formoterol
RS51082B (sr) Sinergistička kombinacija koja uključuje roflumilas i (r.r.) -formoterol
EP4188327B1 (en) Combination therapy for inhalation administration
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol